Skip to main content
SpringerLink
Log in

Le coût du traitement des cancers bronchopulmonaires non à petites cellules (CBNAPC)

The cost of non-small cell lung cancer (NSCLC) treatment

  • Mise au Point / Update
  • Published:
Oncologie

Abstract

Economic consequences of lung cancer treatment are currently increasing, in relation to new drugs or strategy combination. This article describes the burden of diseases such as NSCLC (non-small cell lung cancer) in the first part. In the second part, the economic consequences of first-line and second-line treatment are depicted. The last part describes the impact of targeted therapies and maintenance treatment. Such studies have to be pursued in the future.

Résumé

L’impact économique du coût des cancers est actuellement en augmentation, en relation avec les nouveaux traitements ou la combinaison des stratégies. Cet article décrit les analyses publiées sur les coûts globaux de ces cancers broncho-pulmonaires non à petites cellules (CBNAPC). Dans une seconde partie, les traitements de première ligne et de deuxième ligne sont présentés avec les coûts qu’ils induisent. La dernière partie présente l’impact économique des thérapeutiques ciblées et des traitements de maintenance. La poursuite de telles études est indispensable dans le futur.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Berthelot JM, Will BP, Evans WK, et al. (2000) Decision framework for chemotherapeutic interventions for metastatic nonsmall-cell lung cancer. J Natl Cancer Inst 92: 1321–1329

    Article  PubMed  CAS  Google Scholar 

  2. Bischoff HG, Heigener DF, Walzer S, et al. (2010) Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer 69S1: S18–S23

    Article  Google Scholar 

  3. Bordeleau L (2006) Pharmacoeconomics of systemic therapies for lung cancer. Treat Respir Med 5: 129–141

    Article  PubMed  CAS  Google Scholar 

  4. Braud AC, Levy-Piedbois C, Piedbois P, et al. (2003) Direct treatment costs for patients with lung cancer from first recurrence to death in france. Pharmacoeconomics 21: 671–679

    Article  PubMed  Google Scholar 

  5. Chouaïd C, Atsou K, Hejblum G, Vergnenègre A (2009) Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 27: 113–125

    Article  PubMed  Google Scholar 

  6. Chouaid C, Molinier L, Combescure C, et al. (2004) Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 90: 397–402

    Article  PubMed  CAS  Google Scholar 

  7. Chouaid C, Monnet I, Robinet G, et al. (2007) Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Curr Med Res Opin 23: 1509–1515

    Article  PubMed  Google Scholar 

  8. Chouaïd C, Moser A, Coudray-Omnès C, Vergnenègre A (2008) Conséquences économiques de l’erlotinib dans le traitement des cancers bronchopulmonaires non à petites cellules. Rev Mal Respir 25: 1096–1103

    Article  PubMed  Google Scholar 

  9. Ciuleanu T, Brodowicz T, Zielinski C, et al. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 374: 1432–1440

    Article  PubMed  CAS  Google Scholar 

  10. Côté I LN, Gyldmark M (2006) Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from canadian public health care perspective. Value Health 6: A279

    Article  Google Scholar 

  11. Evans WK (1996) An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer. Semin Oncol 23: 82–89

    PubMed  CAS  Google Scholar 

  12. Evans WK, Will BP, Berthelot JM, Wolfson MC (1995) Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 72: 1270–1277

    Article  PubMed  CAS  Google Scholar 

  13. Evans WK, Will BP, Berthelot JM, Wolfson MC (1995) Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol 5: 408–419

    PubMed  CAS  Google Scholar 

  14. Evans WK, Will BP, Berthelot JM, Wolfson MC (1995) The cost of managing lung cancer in Canada. Oncology (Huntingt) 9: 147–153

    CAS  Google Scholar 

  15. Evans WK, Will BP, Berthelot JM, Wolfson MC (1996) The economics of lung cancer management in Canada [see comments]. Lung Cancer 14: 19–29

    Article  PubMed  CAS  Google Scholar 

  16. Goulart B, Ramsey S (2011) A trial-based assessement of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value in Health 14: 836–845

    Article  PubMed  Google Scholar 

  17. Klein R, Muehlenbein C, Liepa AM, et al. (2009) Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 4: 1404–1414

    Article  PubMed  Google Scholar 

  18. Klein RK, Wielage R, Muehlenbein C, et al. (2010) Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 5: 1263–1272

    Article  PubMed  Google Scholar 

  19. Koopmanschap MA, Van Roijen L, Bonneux L (1994) Current and future costs of cancer. Eur J Cancer 30A: 60–65

    Article  PubMed  CAS  Google Scholar 

  20. Kutikova L, Bowman L, Chang S, et al. (2005) The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 50: 143–154

    Article  PubMed  Google Scholar 

  21. Lewis G, Morlotti L, Creeden J, et al. (2006) Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non small cell lung cancer (SNCL). UK Value Health 6: A203

    Article  Google Scholar 

  22. Nafees B, Stafford M, Gavriel S, et al. (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6: 84

    Article  PubMed  Google Scholar 

  23. Nuijten MJC, Carpeno JC, Chouaid C, et al. (2011) A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non small cell lung cancer. Lung Cancer (In press)

  24. Scagliotti GV, Parikh P, von Pawel J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543–3551

    Article  PubMed  CAS  Google Scholar 

  25. Schiller J, Tilden D, Aristides M, et al. (2004) Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43: 101–112

    Article  PubMed  Google Scholar 

  26. Vergnenègre A, Atsou K, Molinier L, Chouaïd C (2008) Les analyses économiques des cancers bronchopulmonaires (CBP). Rev Mal Respir 25: 3S127–3S137

    PubMed  Google Scholar 

  27. Vergnenègre A, Corre R, Berard H, et al. (2011) Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer. An economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05–06 study. J Thorac Oncol 6: 161–168

    Article  PubMed  Google Scholar 

  28. Vergnenegre A, Molinier L, Combescure C, et al. (2004) Les composants de coût des stratégies de gestion pour le cancer du poumon en France. Rev Mal Respir 21: 501–510

    Article  PubMed  CAS  Google Scholar 

  29. Weissflog D, Matthys H, Hasse J, Virchow Jr JC (2001) L’épidemiologie et le coût du cancer du poumon en Allemagne. Pneumologie 55: 333–338

    Article  PubMed  CAS  Google Scholar 

  30. Wolstenholme JL, Whynes DK (1999) The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 80: 215–218

    Article  PubMed  CAS  Google Scholar 

  31. Zambrowski JJ (2008) Le coût du cancer en France: place des dépenses pharmaceutiques dans la prise en charge des malades en oncologie. Bull Cancer 95: 535–541

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de pathologie respiratoire, CHU de Limoges, hôpital du Cluzeau, 23, avenue D.-Larrey, F-87042, Limoges cedex, France

    A. Vergnenègre

Authors
  1. A. Vergnenègre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Vergnenègre.

About this article

Cite this article

Vergnenègre, A. Le coût du traitement des cancers bronchopulmonaires non à petites cellules (CBNAPC). Oncologie 14, 310–315 (2012). https://doi.org/10.1007/s10269-012-2158-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-012-2158-5

Keywords

Mots clés

Search

Navigation